October 30, 2017 / 12:04 PM / 2 months ago

BRIEF-Mersana announces FDA clearance of IND application for XMT-1536

Oct 30 (Reuters) - Mersana Therapeutics Inc

* Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b

* ‍U.S. FDA cleared company’s investigational new drug application to begin phase 1 clinical trials for XMT-1536​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below